8 December 2017 - - US-based biotechnology company Revance Therapeutics, Inc. (NASDAQ: RVNC) plans to launch an underwritten public offering in which it will issue and sell approximately USD 175m of shares of its common stock, the company said.

In addition, certain stockholders of the company are offering 600,000 shares of the company's common stock for sale to the public.

Revance expects that the underwriters will be granted a 30-day option to purchase from the company and the Selling Stockholders up to an additional 15% of the shares of its common stock offered by the company and the Selling Stockholders.

The company will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Revance said it plans to use the net proceeds received from its offering of common stock for general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs and Co. LLC and Cowen are acting as book-running managers for the proposed offering.

Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialisation of novel botulinum toxin products for multiple aesthetic and therapeutic indications. Revance is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide technology, to address unmet needs in large and growing neurotoxin markets.